MDSpire - Summary
From the Journals

Low-Dose Apixaban Cuts Superficial Thrombosis Risk

Extended anticoagulation lowered symptomatic superficial vein thrombosis in patients with provoked venous thromboembolism.

Share

Extended low-dose apixaban significantly reduces symptomatic superficial vein thrombosis in patients with provoked venous thromboembolism and persistent risk factors, as revealed in a post hoc analysis of the HI-PRO randomized clinical trial. This double-blind study involved adult patients who had completed prior anticoagulation therapy and presented ongoing risk factors. The trial demonstrated a 70% lower likelihood of symptomatic superficial vein thrombosis in patients receiving apixaban compared to placebo, emphasizing the need for further research in this area.

Original Source(s)

Low-Dose Apixaban Cuts Superficial Thrombosis Risk

  • by Andrea Surnit

  • April 2, 2026

Related Content

AGA May Signal Lipids, Female Obesity

Sex-stratified cohort links alopecia to hyperlipidemia in both sexes and obesity in females

Mediterranean Diet Linked to Higher Levels of Mitochondrial Microproteins

Greater adherence was associated with lower oxidative stress markers in older patients.

ACC/AHA Consensus Sets Tricuspid Program Standards

Multisociety document outlines operator, institutional, and registry requirements as transcatheter tricuspid therapies expand